The role of surfactant in lung disease and host defense against pulmonary infections

Annals of the American Thoracic Society

Volumn 12, Issue 5, 2015, Pages 765-774

  Han, SeungHye ^a   Mallampalli, Rama K ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Immune responses; Infection; Pulmonary host defense; Surfactant

Indexed keywords

DIPALMITOYLPHOSPHATIDYLCHOLINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; INTERLEUKIN 8; KERATINOCYTE GROWTH FACTOR; LUNG SURFACTANT; PHOSPHATIDYLETHANOLAMINE; SPHINGOMYELIN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; SURFACTANT PROTEIN D;

ADAPTIVE IMMUNITY; AJELLOMYCES CAPSULATUS; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIGEN ANTIBODY REACTION; ANTIMICROBIAL ACTIVITY; ASPERGILLUS FUMIGATUS; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BREATHING PATTERN; CELL MATURATION; ENTEROBACTER AEROGENES; ESCHERICHIA COLI; GENETIC POLYMORPHISM; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; KLEBSIELLA PNEUMONIAE; LIPID COMPOSITION; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS SURFACE TENSION; LUNG CLEARANCE; LUNG DISEASE; LUNG FUNCTION TEST; LUNG INFECTION; LYMPHOCYTE PROLIFERATION; MEMBRANE PERMEABILITY; MISSENSE MUTATION; MOLECULAR WEIGHT; NEONATAL RESPIRATORY DISTRESS SYNDROME; NONHUMAN; PHOSPHOLIPID SYNTHESIS; PSEUDOMONAS AERUGINOSA; REVIEW; STREPTOCOCCUS AGALACTIAE; SUBSTITUTION THERAPY; SURFACE TENSION; HUMAN; METABOLISM; RESPIRATORY TRACT INFECTION;

HUMANS; LUNG DISEASES; PULMONARY SURFACTANTS; RESPIRATORY TRACT INFECTIONS;

EID: 84929649314     PISSN: 23296933     EISSN: 23256621     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201411-507FR     Document Type: Review

References (157)

1. Neergaard K. Neue Auffassungen über einen Grundbegriff der Atemmechanik. Z Ges Exp Med 1929;66:373-394.
2. Pattle RE. Properties, function and origin of the alveolar lining layer. Nature 1955;175:1125-1126.
3. Clements JA. Surface tension of lung extracts. Proc Soc Exp Biol Med 1957;95:170-172.
4. Avery ME, Said S. Surface phenomena in lungs in health and disease. Medicine (Baltimore) 1965;44:503-526.
5. Wright JR, Clements JA. Metabolism and turnover of lung surfactant. Am Rev Respir Dis 1987;136:426-444.
6. King RJ, Clements JA. Surface active materials from dog lung. I. Method of isolation. Am J Physiol 1972;223:707-714.
7. Veldhuizen R, Nag K, Orgeig S, Possmayer F. The role of lipids in pulmonary surfactant. Biochim Biophys Acta 1998;1408:90-108.
8. Clements J, Tierney D. Alveolar instability associated with altered surface tension. In: Fenn W, Rahn H, editors. Handbook of physiology Section 3: respiration. Vol II. Washington, D.C.: American Physiological Society; 1965. pp. 1565-1583.
9. Weaver TE, Whitsett JA. Function and regulation of expression of pulmonary surfactant-associated proteins. Biochem J 1991;273:249-264.
10. Crouch E, Wright JR. Surfactant proteins a and d and pulmonary host defense. Annu Rev Physiol 2001;63:521-554.
11. Crouch E, Hartshorn K, Ofek I. Collectins and pulmonary innate immunity. Immunol Rev 2000;173:52-65.
12. Crouch EC. Collectins and pulmonary host defense. Am J Respir Cell Mol Biol 1998;19:177-201.
13. Mingarro I, Lukovic D, Vilar M, Pérez-Gil J. Synthetic pulmonary surfactant preparations: new developments and future trends. Curr Med Chem 2008;15:393-403.
14. Schürch D, Ospina OL, Cruz A, Pérez-Gil J. Combined and independent action of proteins SP-B and SP-C in the surface behavior and mechanical stability of pulmonary surfactant films. Biophys J 2010;99:3290-3299.
15. Mulugeta S, Beers MF. Surfactant protein C: its unique properties and emerging immunomodulatory role in the lung. Microbes Infect 2006;8:2317-2323.
16. Blanco O, Pérez-Gil J. Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat Respiratory Distress Syndrome: role of the different components in an efficient pulmonary surfactant. Eur J Pharmacol 2007;568:1-15.
17. Perez-Gil J, Weaver TE. Pulmonary surfactant pathophysiology: current models and open questions. Physiology (Bethesda) 2010;25:132-141.
18. Weaver TE. Pulmonary surfactant-associated proteins. Gen Pharmacol 1988;19:361-368.
19. Voorhout WF, Veenendaal T, Kuroki Y, Ogasawara Y, van Golde LM, Geuze HJ. Immunocytochemical localization of surfactant protein D (SP-D) in type II cells, Clara cells, and alveolar macrophages of rat lung. J Histochem Cytochem 1992;40:1589-1597.
20. Kalina M, Mason RJ, Shannon JM. Surfactant protein C is expressed in alveolar type II cells but not in Clara cells of rat lung. Am J Respir Cell Mol Biol 1992;6:594-600.
21. Wang J, Souza P, Kuliszewski M, Tanswell AK, Post M. Expression of surfactant proteins in embryonic rat lung. Am J Respir Cell Mol Biol 1994;10:222-229.
22. Clements JA. Lung surfactant: a personal perspective. Annu Rev Physiol 1997;59:1-21.
23. Soll R, Ozek E. Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2010;1:CD001079.
24. Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2000;2:CD001079.
25. Wright JR. Immunomodulatory functions of surfactant. Physiol Rev 1997;77:931-962.
26. LeVine AM, Bruno MD, Huelsman KM, Ross GF, Whitsett JA, Korfhagen TR. Surfactant protein A-deficient mice are susceptible to group B streptococcal infection. J Immunol 1997;158:4336-4340.
27. LeVine AM, Kurak KE, Wright JR, Watford WT, Bruno MD, Ross GF, Whitsett JA, Korfhagen TR. Surfactant protein-A binds group B Streptococcus enhancing phagocytosis and clearance from lungs of surfactant protein-A-deficient mice. Am J Respir Cell Mol Biol 1999;20:279-286.
28. LeVine AM, Kurak KE, Bruno MD, Stark JM, Whitsett JA, Korfhagen TR. Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol 1998; 19:700-708.
29. LeVine AM, Gwozdz J, Stark J, Bruno M, Whitsett J, Korfhagen T. Surfactant protein-A enhances respiratory syncytial virus clearance in vivo. J Clin Invest 1999;103:1015-1021.
30. Wu H, Kuzmenko A, Wan S, Schaffer L, Weiss A, Fisher JH, Kim KS, McCormack FX. Surfactant proteins A and D inhibit the growth of gram-negative bacteria by increasing membrane permeability. J Clin Invest 2003;111:1589-1602.
31. McCormack FX, Gibbons R, Ward SR, Kuzmenko A, Wu H, Deepe GS Jr. Macrophage-independent fungicidal action of the pulmonary collectins. J Biol Chem 2003;278:36250-36256.
32. Floros J, Wang G, Mikerov AN. Genetic complexity of the human innate host defense molecules, surfactant protein A1 (SP-A1) and SP-A2 - impact on function. Crit Rev Eukaryot Gene Expr 2009;19:125-137.
33. Brinker KG, Garner H, Wright JR. Surfactant protein A modulates the differentiation of murine bone marrow-derived dendritic cells. Am J Physiol Lung Cell Mol Physiol 2003;284:L232-L241.
34. Cheng G, Ueda T, Nakajima H, Nakajima A, Kinjyo S, Motojima S, Fukuda T. Suppressive effects of SP-A on ionomycin-induced IL-8 production and release by eosinophils. Int Arch Allergy Immunol 1998;117:59-62.
35. Wang JY, Shieh CC, You PF, Lei HY, Reid KB. Inhibitory effect of pulmonary surfactant proteins A and D on allergen-induced lymphocyte proliferation and histamine release in children with asthma. Am J Respir Crit Care Med 1998;158:510-518.
36. Malhotra R, Haurum J, Thiel S, Jensenius JC, Sim RB. Pollen grains bind to lung alveolar type II cells (A549) via lung surfactant protein A (SP-A). Biosci Rep 1993;13:79-90.
37. Wang JY, Kishore U, Lim BL, Strong P, Reid KB. Interaction of human lung surfactant proteins A and D with mite (Dermatophagoides pteronyssinus) allergens. Clin Exp Immunol 1996;106:367-373.
38. Madan T, Kishore U, Shah A, Eggleton P, Strong P, Wang JY, Aggrawal SS, Sarma PU, Reid KB. Lung surfactant proteins A and D can inhibit specific IgE binding to the allergens of Aspergillus fumigatus and block allergen-induced histamine release from human basophils. Clin Exp Immunol 1997;110:241-249.
39. Faro A, Hamvas A. Lung transplantation for inherited disorders of surfactant metabolism. NeoReviews 2008;9:e468-e476.
40. Gregory TJ, Longmore WJ, Moxley MA, Whitsett JA, Reed CR, Fowler AA III, Hudson LD, Maunder RJ, Crim C, Hyers TM. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991;88:1976-1981.
41. Hallman M, Spragg R, Harrell JH, Moser KM, Gluck L. Evidence of lung surfactant abnormality in respiratory failure: study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982;70:673-683.
42. Davidson WJ, Dorscheid D, Spragg R, Schulzer M, Mak E, Ayas NT. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a metaanalysis. Crit Care 2006;10:R41.
43. Chida S, Phelps DS, Soll RF, Taeusch HW. Surfactant proteins and anti-surfactant antibodies in sera from infants with respiratory distress syndrome with and without surfactant treatment. Pediatrics 1991;88:84-89.
44. Doyle IR, Nicholas TE, Bersten AD. Serum surfactant protein-A levels in patients with acute cardiogenic pulmonary edema and adult respiratory distress syndrome. Am J Respir Crit Care Med 1995;152:307-317.
45. Jobe A, Ikegami M, Jacobs H, Jones S, Conaway D. Permeability of premature lamb lungs to protein and the effect of surfactant on that permeability. J Appl Physiol 1983;55:169-176.
46. Robertson B, Curstedt T, Herting E, Sun B, Akino T, Schäfer KP. Alveolar-to-vascular leakage of surfactant protein A in ventilated immature newborn rabbits. Biol Neonate 1995;68:185-190.
47. Delgado C, Krötzsch E, Jiménez-Alvarez LA, Ramírez-Martínez G, Márquez-García JE, Cruz-Lagunas A, Morán J, Hernández C, Sierra-Vargas P, Avila-Moreno F, et al. Serum Surfactant Protein D (SP-D) is a Prognostic Marker of Poor Outcome in Patients with A/H1N1 Virus Infection. Lung 2015;193:25-30.
48. Kuroki Y, Takahashi H, Chiba H, Akino T. Surfactant proteins A and D: disease markers. Biochim Biophys Acta 1998;1408:334-345.
49. Selman M, Lin HM, Montaño M, Jenkins AL, Estrada A, Lin Z, Wang G, DiAngelo SL, Guo X, Umstead TM, et al. Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum Genet 2003;113:542-550.
50. Lawson WE, Grant SW, Ambrosini V, Womble KE, Dawson EP, Lane KB, Markin C, Renzoni E, Lympany P, Thomas AQ, et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax 2004;59:977-980.
51. Sumita Y, Sugiura T, Kawaguchi Y, Baba S, Soejima M, Murakawa Y, Hara M, Kamatani N. Genetic polymorphisms in the surfactant proteins in systemic sclerosis in Japanese: T/T genotype at 1580 C/T (Thr131Ile) in the SP-B gene reduces the risk of interstitial lung disease. Rheumatology (Oxford) 2008;47:289-291.
52. Saxena S, Kumar R, Madan T, Gupta V, Muralidhar K, Sarma PU. Association of polymorphisms in pulmonary surfactant protein A1 and A2 genes with high-altitude pulmonary edema. Chest 2005;128:1611-1619.
53. Lin Z, Pearson C, Chinchilli V, Pietschmann SM, Luo J, Pison U, Floros J. Polymorphisms of human SP-A, SP-B, and SP-D genes: association of SP-B Thr131Ile with ARDS. Clin Genet 2000;58:181-191.
54. Seifart C, Lin HM, Seifart U, Plagens A, DiAngelo S, von Wichert P, Floros J. Rare SP-A alleles and the SP-A1-6A(4) allele associate with risk for lung carcinoma. Clin Genet 2005;68:128-136.
55. Pavlovic J, Papagaroufalis C, Xanthou M, Liu W, Fan R, Thomas NJ, Apostolidou I, Papathoma E, Megaloyianni E, DiAngelo S, et al. Genetic variants of surfactant proteins A, B, C, and D in bronchopulmonary dysplasia. Dis Markers 2006;22:277-291.
56. Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, Rosenblatt RL, DiMaio JM, Kinch LN, Grishin NV, Garcia CK. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 2009;84:52-59.
57. Henderson FC, Miakotina OL, Mallampalli RK. Proapoptotic effects of P. aeruginosa involve inhibition of surfactant phosphatidylcholine synthesis. J Lipid Res 2006;47:2314-2324.
58. Wu Y, Xu Z, Henderson FC, Ryan AJ, Yahr TL, Mallampalli RK. Chronic Pseudomonas aeruginosa infection reduces surfactant levels by inhibiting its biosynthesis. Cell Microbiol 2007;9:1062-1072.
59. Malloy JL, Veldhuizen RA, Thibodeaux BA, O'Callaghan RJ, Wright JR. Pseudomonas aeruginosa protease IV degrades surfactant proteins and inhibits surfactant host defense and biophysical functions. Am J Physiol Lung Cell Mol Physiol 2005;288:L409-L418.
60. Mariencheck WI, Alcorn JF, Palmer SM, Wright JR. Pseudomonas aeruginosa elastase degrades surfactant proteins A and D. Am J Respir Cell Mol Biol 2003;28:528-537.
61. Kuang Z, Hao Y, Walling BE, Jeffries JL, Ohman DE, Lau GW. Pseudomonas aeruginosa elastase provides an escape from phagocytosis by degrading the pulmonary surfactant protein-A. PLoS One 2011;6:e27091.
62. Miakotina OL, McCoy DM, Shi L, Look DC, Mallampalli RK. Human adenovirus modulates surfactant phospholipid trafficking. Traffic 2007;8:1765-1777.
63. Haczku A, Atochina EN, Tomer Y, Chen H, Scanlon ST, Russo S, Xu J, Panettieri RA Jr, Beers MF. Aspergillus fumigatus-induced allergic airway inflammation alters surfactant homeostasis and lung function in BALB/c mice. Am J Respir Cell Mol Biol 2001;25:45-50.
64. Bruce SR, Atkins CL, Colasurdo GN, Alcorn JL. Respiratory syncytial virus infection alters surfactant protein A expression in human pulmonary epithelial cells by reducing translation efficiency. Am J Physiol Lung Cell Mol Physiol 2009;297:L559-L567.
65. Nayak A, Dodagatta-Marri E, Tsolaki AG, Kishore U. An insight into the diverse roles of surfactant proteins, SP-A and SP-D in innate and adaptive immunity. Front Immunol 2012;3:131.
66. Kabha K, Schmegner J, Keisari Y, Parolis H, Schlepper-Schaeffer J, Ofek I. SP-A enhances phagocytosis of Klebsiella by interaction with capsular polysaccharides and alveolar macrophages. Am J Physiol 1997;272:L344-L352.
67. Kuan SF, Rust K, Crouch E. Interactions of surfactant protein D with bacterial lipopolysaccharides. Surfactant protein D is an Escherichia coli-binding protein in bronchoalveolar lavage. J Clin Invest 1992;90:97-106.
68. Kuang Z, Hao Y, Hwang S, Zhang S, Kim E, Akinbi HT, Schurr MJ, Irvin RT, Hassett DJ, Lau GW. The Pseudomonas aeruginosa flagellum confers resistance to pulmonary surfactant protein-A by impacting the production of exoproteases through quorumsensing. Mol Microbiol 2011;79:1220-1235.
69. Lim BL, Wang JY, Holmskov U, Hoppe HJ, Reid KB. Expression of the carbohydrate recognition domain of lung surfactant protein D and demonstration of its binding to lipopolysaccharides of gram-negative bacteria. Biochem Biophys Res Commun 1994;202:1674-1680.
70. Restrepo CI, Dong Q, Savov J, Mariencheck WI, Wright JR. Surfactant protein D stimulates phagocytosis of Pseudomonas aeruginosa by alveolar macrophages. Am J Respir Cell Mol Biol 1999;21:576-585.
71. Sawada K, Ariki S, Kojima T, Saito A, Yamazoe M, Nishitani C, Shimizu T, Takahashi M, Mitsuzawa H, Yokota S, et al. Pulmonary collectins protect macrophages against pore-forming activity of Legionella pneumophila and suppress its intracellular growth. J Biol Chem 2010;285:8434-8443.
72. McNeely TB, Coonrod JD. Comparison of the opsonic activity of human surfactant protein A for Staphylococcus aureus and Streptococcus pneumoniae with rabbit and human macrophages. J Infect Dis 1993;167:91-97.
73. Hartshorn KL, Crouch E, White MR, Colamussi ML, Kakkanatt A, Tauber B, Shepherd V, Sastry KN. Pulmonary surfactant proteins A and D enhance neutrophil uptake of bacteria. Am J Physiol 1998;274:L958-L969.
74. Piboonpocanun S, Chiba H, Mitsuzawa H, Martin W, Murphy RC, Harbeck RJ, Voelker DR. Surfactant protein A binds Mycoplasma pneumoniae with high affinity and attenuates its growth by recognition of disaturated phosphatidylglycerols. J Biol Chem 2005;280:9-17.
75. Ferguson JS, Voelker DR, McCormack FX, Schlesinger LS. Surfactant protein D binds to Mycobacterium tuberculosis bacilli and lipoarabinomannan via carbohydrate-lectin interactions resulting in reduced phagocytosis of the bacteria by macrophages. J Immunol 1999;163:312-321.
76. Kudo K, Sano H, Takahashi H, Kuronuma K, Yokota S, Fujii N, Shimada K, Yano I, Kumazawa Y, Voelker DR, et al. Pulmonary collectins enhance phagocytosis of Mycobacterium avium through increased activity of mannose receptor. J Immunol 2004;172:7592-7602.
77. Shepherd VL. Pulmonary surfactant protein D: a novel link between innate and adaptive immunity. Am J Physiol Lung Cell Mol Physiol 2002;282:L516-L517.
78. Ragas A, Roussel L, Puzo G, Rivière M. The Mycobacterium tuberculosis cell-surface glycoprotein apa as a potential adhesin to colonize target cells via the innate immune system pulmonary C-type lectin surfactant protein A. J Biol Chem 2007;282:5133-5142.
79. Madan T, Eggleton P, Kishore U, Strong P, Aggrawal SS, Sarma PU, Reid KB. Binding of pulmonary surfactant proteins A and D to Aspergillus fumigatus conidia enhances phagocytosis and killing by human neutrophils and alveolar macrophages. Infect Immun 1997;65:3171-3179.
80. Lekkala M, LeVine AM, Linke MJ, Crouch EC, Linders B, Brummer E, Stevens DA. Effect of lung surfactant collectins on bronchoalveolar macrophage interaction with Blastomyces dermatitidis: inhibition of tumor necrosis factor alpha production by surfactant protein D. Infect Immun 2006;74:4549-4556.
81. Awasthi S, Magee DM, Coalson JJ. Coccidioides posadasii infection alters the expression of pulmonary surfactant proteins (SP)-A and SP-D. Respir Res 2004;5:28.
82. Schelenz S, Malhotra R, Sim RB, Holmskov U, Bancroft GJ. Binding of host collectins to the pathogenic yeast Cryptococcus neoformans: human surfactant protein D acts as an agglutinin for acapsular yeast cells. Infect Immun 1995;63:3360-3366.
83. Walenkamp AM, Verheul AF, Scharringa J, Hoepelman IM. Pulmonary surfactant protein A binds to Cryptococcus neoformans without promoting phagocytosis. Eur J Clin Invest 1999;29:83-92.
84. Yong SJ, Vuk-Pavlovic Z, Standing JE, Crouch EC, Limper AH. Surfactant protein D-mediated aggregation of Pneumocystis carinii impairs phagocytosis by alveolar macrophages. Infect Immun 2003;71:1662-1671.
85. Zimmerman PE, Voelker DR, McCormack FX, Paulsrud JR, Martin WJ II. 120-kD surface glycoprotein of Pneumocystis carinii is a ligand for surfactant protein A. J Clin Invest 1992;89:143-149.
86. van Rozendaal BA, van Spriel AB, van De Winkel JG, Haagsman HP. Role of pulmonary surfactant protein D in innate defense against Candida albicans. J Infect Dis 2000;182:917-922.
87. Rosseau S, Guenther A, Seeger W, Lohmeyer J. Phagocytosis of viable Candida albicans by alveolar macrophages: lack of opsonin function of surfactant protein A. J Infect Dis 1997;175:421-428.
88. Hartshorn KL, White MR, Voelker DR, Coburn J, Zaner K, Crouch EC. Mechanism of binding of surfactant protein D to influenza A viruses: importance of binding to haemagglutinin to antiviral activity. Biochem J 2000;351:449-458.
89. Hillaire ML, Haagsman HP, Osterhaus AD, Rimmelzwaan GF, van Eijk M. Pulmonary surfactant protein D in first-line innate defence against influenza A virus infections. J Innate Immun 2013;5:197-208.
90. Hartshorn KL, Sastry KN, Chang D, White MR, Crouch EC. Enhanced anti-influenza activity of a surfactant protein D and serum conglutinin fusion protein. Am J Physiol Lung Cell Mol Physiol 2000;278:L90-L98.
91. Qi L, Kash JC, Dugan VG, Jagger BW, Lau YF, Sheng ZM, Crouch EC, Hartshorn KL, Taubenberger JK. The ability of pandemic influenza virus hemagglutinins to induce lower respiratory pathology is associated with decreased surfactant protein D binding. Virology 2011;412:426-434.
92. Meschi J, Crouch EC, Skolnik P, Yahya K, Holmskov U, Leth-Larsen R, Tornoe I, Tecle T, White MR, Hartshorn KL. Surfactant protein D binds to human immunodeficiency virus (HIV) envelope protein gp120 and inhibits HIV replication. J Gen Virol 2005;86:3097-3107.
93. Pandit H, Gopal S, Sonawani A, Yadav AK, Qaseem AS, Warke H, Patil A, Gajbhiye R, Kulkarni V, Al-Mozaini MA, et al. Surfactant protein D inhibits HIV-1 infection of target cells via interference with gp120-CD4 interaction and modulates pro-inflammatory cytokine production. PLoS One 2014;9:e102395.
94. Hickling TP, Bright H, Wing K, Gower D, Martin SL, Sim RB, Malhotra R. A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo. Eur J Immunol 1999;29:3478-3484.
95. Leth-Larsen R, Zhong F, Chow VT, Holmskov U, Lu J. The SARS coronavirus spike glycoprotein is selectively recognized by lung surfactant protein D and activates macrophages. Immunobiology 2007;212:201-211.
96. Numata M, Kandasamy P, Nagashima Y, Fickes R, Murphy RC, Voelker DR. Phosphatidylinositol inhibits respiratory syncytial virus infection. J Lipid Res 2015;56:578-587.
97. Hintz SR, Poole WK, Wright LL, Fanaroff AA, Kendrick DE, Laptook AR, Goldberg R, Duara S, Stoll BJ, Oh W; NICHD Neonatal Research Network. Changes in mortality and morbidities among infants born at less than 25 weeks during the post-surfactant era. Arch Dis Child Fetal Neonatal Ed 2005;90:F128-F133.
98. Hoekstra RE, Jackson JC, Myers TF, Frantz ID III, Stern ME, Powers WF, Maurer M, Raye JR, Carrier ST, Gunkel JH, et al. Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome. Pediatrics 1991;88:10-18.
99. Liechty EA, Donovan E, Purohit D, Gilhooly J, Feldman B, Noguchi A, Denson SE, Sehgal SS, Gross I, Stevens D, et al. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics 1991;88:19-28.
100. Seger N, Soll R. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst Rev 2009;2:CD007836.
101. Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, Saugstad OD, Simeoni U, Speer CP, Halliday HL; European Association of Perinatal Medicine. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants - 2010 update. Neonatology 2010;97:402-417.
102. Committee on Fetus and Newborn; American Academy of Pediatrics. Respiratory support in preterm infants at birth. Pediatrics 2014;133: 171-174.
103. Polin RA, Carlo WA; Committee on Fetus and Newborn; American Academy of Pediatrics. Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics 2014;133:156-163.
104. Tarawneh A, Kaczmarek J, Bottino MN, Sant'anna GM. Severe airway obstruction during surfactant administration using a standardized protocol: a prospective, observational study. J Perinatol 2012;32:270-275.
105. Al Ethawi Y. Preliminary evaluation of a new technique of minimally invasive surfactant therapy. J Clin Neonatol 2012;1:66-68.
106. Dargaville PA, Aiyappan A, Cornelius A, Williams C, De Paoli AG. Preliminary evaluation of a new technique of minimally invasive surfactant therapy. Arch Dis Child Fetal Neonatal Ed 2011;96:F243-F248.
107. Abdel-Latif ME, Osborn DA. Laryngeal mask airway surfactant administration for prevention of morbidity and mortality in preterm infants with or at risk of respiratory distress syndrome. Cochrane Database Syst Rev 2011;7:CD008309.
108. Göpel W, Kribs A, Ziegler A, Laux R, Hoehn T, Wieg C, Siegel J, Avenarius S, von der Wense A, Vochem M, et al.; German Neonatal Network. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet 2011;378:1627-1634.
109. Kanmaz HG, Erdeve O, Canpolat FE, Mutlu B, Dilmen U. Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics 2013;131:e502-e509.
110. Spragg RG, Lewis JF, Wurst W, Häfner D, Baughman RP, Wewers MD, Marsh JJ. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003;167:1562-1566.
111. Weg JG, Balk RA, Tharratt RS, Jenkinson SG, Shah JB, Zaccardelli D, Horton J, Pattishall EN. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA 1994;272:1433-1438.
112. Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventós AA, Lemaire F, Long W, Zaccardelli DS, Pattishall EN; Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996;334:1417-1421.
113. Spragg RG, Lewis JF, Walmrath HD, Johannigman J, Bellingan G, Laterre PF, Witte MC, Richards GA, Rippin G, Rathgeb F, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004;351:884-892.
114. Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ, Moxley MA, Cai GZ, Hite RD, Smith RM, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997;155:1309-1315.
115. Gunther A, Siebert C, Schmidt R, Ziegler S, Grimminger F, Yabut M, Temmesfeld B, Walmrath D, Morr H, Seeger W. Surfactant alterations in severe pneumonia, acute respiratory distress syndrome, and cardiogenic lung edema. Am J Respir Crit Care Med 1996;153:176-184.
116. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J 1999;13:1455-1476.
117. Kurashima K, Ogawa H, Ohka T, Fujimura M, Matsuda T, Kobayashi T. A pilot study of surfactant inhalation in the treatment of asthmatic attack. Arerugi 1991;40:160-163.
118. Oetomo SB, Dorrepaal C, Bos H, Gerritsen J, van der Mark TW, Koëter GH, van Aalderen WM. Surfactant nebulization does not alter airflow obstruction and bronchial responsiveness to histamine in asthmatic children. Am J Respir Crit Care Med 1996;153:1148-1152.
119. Mikawa K, Maekawa N, Nishina K, Takao Y, Yaku H, Obara H. Selective intrabronchial instillation of surfactant in a patient with pneumonia: a preliminary report. Eur Respir J 1993;6:1563-1566.
120. Marriage SC, Underhill H, Nadel S. Use of natural surfactant in an HIV-infected infant with Pneumocystis carinii pneumonia. Intensive Care Med 1996;22:611-612.
121. Creery WD, Hashmi A, Hutchison JS, Singh RN. Surfactant therapy improves pulmonary function in infants with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome. Pediatr Pulmonol 1997;24:370-373.
122. Vos GD, Rijtema MN, Blanco CE. Treatment of respiratory failure due to respiratory syncytial virus pneumonia with natural surfactant. Pediatr Pulmonol 1996;22:412-415.
123. Anzueto A, Jubran A, Ohar JA, Piquette CA, Rennard SI, Colice G, Pattishall EN, Barrett J, Engle M, Perret KA, et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA 1997;278:1426-1431.
124. Allen JN, Moore SA, Pope-Harman AL, Marsh CB, Wewers MD. Immunosuppressive properties of surfactant and plasma on alveolar macrophages. J Lab Clin Med 1995;125:356-369.
125. Antal JM, Divis LT, Erzurum SC, Wiedemann HP, Thomassen MJ. Surfactant suppresses NF-kappa B activation in human monocytic cells. Am J Respir Cell Mol Biol 1996;14:374-379.
126. Thomassen MJ, Antal JM, Barna BP, Divis LT, Meeker DP, Wiedemann HP. Surfactant downregulates synthesis of DNA and inflammatory mediators in normal human lung fibroblasts. Am J Physiol 1996;270:L159-L163.
127. Bartmann P, Bamberger U, Pohlandt F, Gortner L. Immunogenicity and immunomodulatory activity of bovine surfactant (SF-RI 1). Acta Paediatr 1992;81:383-388.
128. Bartmann P, Gortner L, Pohlandt F, Jaeger H. In vitro lymphocyte functions in the presence of bovine surfactant and its phospholipid fractions. J Perinat Med 1992;20:189-196.
129. Roth MD, Pinto M, Golub SH, Shau H. Pulmonary surfactant inhibits interleukin-2-induced proliferation and the generation of lymphokine-activated killer cells. Am J Respir Cell Mol Biol 1993;9:652-658.
130. Birkun AA, Kubyshkin AV, Novikov NY, Krivorutchenko YL, Fedosov MI, Postnikova ON, Snitser AA. Joint intratracheal surfactantantibacterial therapy in experimental Pseudomonas-induced pneumonia. J Aerosol Med Pulm Drug Deliv [online ahead of print] 17 Dec 2014; DOI:10.1089/jamp.2014.1161
131. Ballard PL, Ballard RA. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol 1995;173:254-262.
132. Ballard PL, Hovey ML, Gonzales LK. Thyroid hormone stimulation of phosphatidylcholine synthesis in cultured fetal rabbit lung. J Clin Invest 1984;74:898-905.
133. Ikegami M, Polk D, Tabor B, Lewis J, Yamada T, Jobe A. Corticosteroid and thyrotropin-releasing hormone effects on preterm sheep lung function. J Appl Physiol (1985) 1991;70:2268-2278.
134. Gonzalez Garay AG, Reveiz L, Velasco Hidalgo L, Solis Galicia C. Ambroxol for women at risk of preterm birth for preventing neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2014;10:CD009708.
135. Rosen DM, Waltz DA. Hydroxychloroquine and surfactant protein C deficiency. N Engl J Med 2005;352:207-208.
136. Hepping N, Griese M, Lohse P, Garbe W, Lange L. Successful treatment of neonatal respiratory failure caused by a novel surfactant protein C p.Cys121Gly mutation with hydroxychloroquine. J Perinatol 2013;33:492-494.
137. Rabach I, Poli F, Zennaro F, Germani C, Ventura A, Barbi E. Is treatment with hydroxychloroquine effective in surfactant protein C deficiency? Arch Bronconeumol 2013;49:213-215.
138. Beers MF. Inhibition of cellular processing of surfactant protein C by drugs affecting intracellular pH gradients. J Biol Chem 1996;271:14361-14370.
139. Xu X, McCormick-Shannon K, Voelker DR, Mason RJ. KGF increases SP-A and SP-D mRNA levels and secretion in cultured rat alveolar type II cells. Am J Respir Cell Mol Biol 1998;18:168-178.
140. Hallman M, Merritt TA, Pohjavuori M, Gluck L. Effect of surfactant substitution on lung effluent phospholipids in respiratory distress syndrome: evaluation of surfactant phospholipid turnover, pool size, and the relationship to severity of respiratory failure. Pediatr Res 1986;20:1228-1235.
141. Stevens PA, Schadow B, Bartholain S, Segerer H, Obladen M. Surfactant protein A in the course of respiratory distress syndrome. Eur J Pediatr 1992;151:596-600.
142. Moya FR, Montes HF, Thomas VL, Mouzinho AM, Smith JF, Rosenfeld CR. Surfactant protein A and saturated phosphatidylcholine in respiratory distress syndrome. Am J Respir Crit Care Med 1994;150:1672-1677.
143. Hallman M, Merritt TA, Akino T, Bry K. Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants. Am Rev Respir Dis 1991;144:1376-1384.
144. Singh G, Katyal SL, Bedrossian CW, Rogers RM. Pulmonary alveolar proteinosis. Staining for surfactant apoprotein in alveolar proteinosis and in conditions simulating it. Chest 1983;83:82-86.
145. Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, Abe S. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995;152:1860-1866.
146. Akino T, Okano G, Ohno K. Alveolar phospholipids in pulmonary alveolar proteinosis. Tohoku J Exp Med 1978;126:51-62.
147. Pison U, Obertacke U, Seeger W, Hawgood S. Surfactant protein A (SP-A) is decreased in acute parenchymal lung injury associated with polytrauma. Eur J Clin Invest 1992;22:712-718.
148. McCormack FX, King TE Jr, Voelker DR, Robinson PC, Mason RJ. Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A. Am Rev Respir Dis 1991;144:160-166.
149. Honda Y, Tsunematsu K, Suzuki A, Akino T. Changes in phospholipids in bronchoalveolar lavage fluid of patients with interstitial lung diseases. Lung 1988;166:293-301.
150. Robinson PC, Watters LC, King TE, Mason RJ. Idiopathic pulmonary fibrosis. Abnormalities in bronchoalveolar lavage fluid phospholipids. Am Rev Respir Dis 1988;137:585-591.
151. Hamm H, Lührs J, Guzman y Rotaeche J, Costabel U, Fabel H, Bartsch W. Elevated surfactant protein A in bronchoalveolar lavage fluids from sarcoidosis and hypersensitivity pneumonitis patients. Chest 1994;106:1766-1770.
152. Low RB, Davis GS, Bell DY, Giancola MS, Vacek PM. Lipids in bronchoalveolar lavage fluid from patients with sarcoidosis. Thorax 1987;42:926-932.
153. Baughman RP, Sternberg RI, Hull W, Buchsbaum JA, Whitsett J. Decreased surfactant protein A in patients with bacterial pneumonia. Am Rev Respir Dis 1993;147:653-657.
154. Baughman RP, Stein E, MacGee J, Rashkin M, Sahebjami H. Changes in fatty acids in phospholipids of the bronchoalveolar fluid in bacterial pneumonia and in adult respiratory distress syndrome. Clin Chem 1984;30:521-523.
155. Honda Y, Takahashi H, Kuroki Y, Akino T, Abe S. Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers. Chest 1996;109:1006-1009.
156. Low RB, Davis GS, Giancola MS. Biochemical analyses of bronchoalveolar lavage fluids of healthy human volunteer smokers and nonsmokers. Am Rev Respir Dis 1978;118:863-875.
157. van de Graaf EA, Jansen HM, Lutter R, Alberts C, Kobesen J, de Vries IJ, Out TA. Surfactant protein A in bronchoalveolar lavage fluid. J Lab Clin Med 1992;120:252-263.